Avita Medical Inc Expected To Post A Loss Of 43 Cents A Share: Earnings Preview

AVITA Medical

11/02/2025 21:25

* AVITA Medical Inc  RCEL.OQ   RCEL.O  is expected to show a
rise
in quarterly revenue when it reports  results on February 13 for
the period ending December 31 2024
    * The Valencia California California-based  company is
expected to
report a 48.2% increase in revenue to $21.043 million from $14.2
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for AVITA Medical Inc is for
a
loss of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for AVITA
Medical Inc
is $15.00​, above​ its last closing price of $8.80. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.44       -0.44      -0.62     Missed  -42.1
 Jun. 30 2024  -0.52       -0.52      -0.60     Missed  -15.8
 Mar. 31 2024  -0.45       -0.47      -0.73     Missed  -54.3​
 Dec. 31 2023  -0.36       -0.37      -0.28     Beat    25.2
 ​​Sep.        -0.45       -0.44      -0.34     Beat    23.4
 30 2023                                                
 Jun. 30 2023  -0.32       -0.32      -0.41     Missed  -26.4​
 Mar. 31 2023  -0.23       -0.25      -0.37     Missed  -47.4
 Dec. 31 2022  -0.28       -0.29      -0.22     Beat    24.7
 This summary was machine generated February 11 at 21:25 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)